Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/59585
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2030-12-31
Coleções
Metadata
Mostrar registro completo
EXPLOITING LIPIDS TO DEVELOP ANTICRYPTOCOCCAL VACCINES
Immunogenic lipids
Glucosylceramide
Sterylglycosides
Extracellular vesicles
Antifungal vaccine
Afiliação
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brazil.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA / Department of Medicine. Division of Infectious Diseases. Stony Brook University. Stony Brook, USA / Veterans Administration Medical Center. Northport, USA.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brazil.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA / Department of Medicine. Division of Infectious Diseases. Stony Brook University. Stony Brook, USA / Veterans Administration Medical Center. Northport, USA.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Purpose of Review Cryptococcus spp. are responsible for life-threatening infections in humans causing mortality rates of 70% in developing countries. Antifungal therapy to combat cryptococcosis is based on the combination of amphotericin B, azoles, and 5-flucytosine. However, treatment failure is frequently triggered by antifungal resistance, drug-drug interactions, and toxicity. New alternatives to prevent cryptococcosis are imperative. Here, we discuss the roles of lipids in the immunological control of the disease caused by Cryptococcus spp.Recent FindingsRecently, remarkable advances on immunology of fungal infections have been made and a number of studies indicated the potential of vaccine formulations to combat cryptococcosis. New formulations exploiting virulence regulators and genetically modified attenuated strains have been tested. In this context, lipids have emerged as virulence regulators and immunogens to be explored.SummaryGlucosylceramide (GlcCer), sterylglycosides (SGs), and lipid-containing extracellular vesicles have been recently tested in vaccine formulations and their anticryptococcal efficacy was confirmed in vivo. Together, the data discussed here encourage the use of fungal lipids in anticryptococcal vaccinal strategies.
Palavras-chave em inglês
CryptococcosisImmunogenic lipids
Glucosylceramide
Sterylglycosides
Extracellular vesicles
Antifungal vaccine
Compartilhar